Ebola virus disease
An experimental drug developed by a US-based team of researchers led by a Greek scientist has been shown to dramatically improve survival rates for the deadly Ebola haemorrhagic fever.
The antibody cocktail called REGN-EB3 was developed by Regeneron Pharmaceuticals where Dr Christos Kyratsous is vice president of research, infectious diseases and viral vector technologies.
The situation had become critical when the virus had spread to the city of Goma, home to two million citizens. This city is situated on the border with Uganda, and Congo officials claim that a priest who used several false names brought the disease into the city.
A 17-year-old Italian tourist died of meningitis in a hospital in Athens on Wednesday morning, according to the initial lab results conducted by the doctors.
A Greek Air Force aircraft transferred the woman from Naxos, where she was holidaying with her family, to the Nikea hospital on Tuesday, after she developed high fever and went into septic shock. She died at the hospital.
The number of people killed in an Ebola outbreak in eastern DR Congo has risen to 443, health authorities have announced, as new President Felix Tshisekedi began his first full day in office on Jan. 25.
DR Congo on Tuesday officially declared the end of an outbreak of Ebola, bringing the curtain down on a 10-week re-emergence of the disease which claimed 33 lives.
The Red Cross has confirmed that more than $5m (£3.8m) of aid money was lost to fraud and corruption during the Ebola epidemic in West Africa.
Auditors found overpriced supplies, salaries for non-existent aid workers and fake customs bills.
The disease, which raged between 2014 and 2016, claimed at least 10,000 lives.